Boston Scientific Corporation (NYSE:BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the Company’s next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent, designed to provide physicians improved DES performance in treating patients with coronary artery disease, is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug. The Company plans to begin marketing the product in the U.S. immediately.
To view Multimedia News Release, go to http://www.multivu.com/mnr/43510-boston-scientific-fda-promus-element-plus-platinum-chromium-stent-system
Sanjay\\\'s research has been reviewed favorably by internationally reputed scientists. Some of his research has even appeared in international, peer-reviewed scientific journals. Sanjay\\\'s research on the new agreements between spirituality and science is the first ever to get published in such high-ranking journals. This is the gold standard in scientific research and a landmark of superb research on the subject of science and religion or science and spirituality. Visit http://www.SanjayCPatel.com
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced Accelrys Insight and Accelrys Insight for Excel, completing the roll-out of Accelrys’ next-generation cheminformatics suite and providing an interactive, collaborative environment for rapid and effective decision-making in drug discovery. Accelrys Insight and Accelrys Insight for Excel offer research scientists an entirely new way of accessing, visualizing and analyzing data that is locked in disparate locations across internal discovery teams and networked external partners, helping to lower long-standing barriers to bringing innovative therapeutics to market faster and more cost effectively.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62191-accelrys-insight-next-generation-decision-making-in-scientific-discovery
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
International research led by University College London (UCL) as part of the ‘Cities Changing Diabetes’ partnership programme challenges current scientific understanding of the rapid rise of diabetes in cities. The findings suggest that in cities around the world, social and cultural factors play a far more important role in the spread of the epidemic than previously thought.
More than two thirds of the world’s 400 million people with diabetes live in urban areas.1,2 The year-long study for Cities Changing Diabetes, a unique public-private-academic partnership, sought to better understand what makes people vulnerable to type 2 diabetes in cities in order to inform solutions for one of the most pressing modern-day public health challenges. To explore this complex issue, more than 550 interviews were undertaken with at-risk and diagnosed people in five major cities – Copenhagen, Houston, Mexico City, Shanghai and Tianjin.
“By largely focusing on biomedical risk factors for diabetes, traditional research has not adequately accounted for the impact of social and cultural drivers of disease,” says David Napier, Professor of Medical Anthropology, UCL. “Our pioneering research will enable cities worldwide to help populations adapt to lifestyles that make them less vulnerable to diabetes.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7690951-study-rethink-rise-diabetes-in-cities/
Through thousands of hours meeting with women from Dallas to Taipei, Sao Paulo to Paris, Neutrogena® uncovered a universal truth – women are stepping back to examine what’s possible in their lives so they can pursue their dreams. Always on a mission to create, innovate, and rethink what’s possible in skincare, Neutrogena® identified this shared value and was inspired to launch its first-ever global campaign: “Neutrogena. See What’s Possible.™”
“Neutrogena® started as a dream, and through scientific discovery, creative thinking and the resilience to defy expectations without any compromises, a brand was born,” said Alicia Sontag, President, Beauty Care, Johnson & Johnson Consumer Inc. “We support women around the world and are proud to help them put their best face forward as they pursue their own dreams – big or small.”
The “Neutrogena. See What’s Possible™” campaign will debut with a commercial voiced by Brand Ambassador and creative consultant Kerry Washington which features real women following their passions. The empowering video brings to life the brand’s point of view on beauty – what really makes a woman beautiful is the ability to look in the mirror and know that anything is possible. In addition, educational and inspiring digital content designed to encourage her along her journey will be leveraged through social platforms in over 27 countries around the world, making this the largest digitally-driven campaign the brand has ever executed.
To view the multimedia release go to:
http://www.multivu.com/players/English/7770451-neutrogena-see-what-s-possible/
Investment in basic research, convergence across disciplines and better engagement between academia and industry are key to the future of innovation, according to a panel of renowned thought leaders speaking at the celebration of the 2013 Dr. Paul Janssen Award for Biomedical Research.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63340-johnson-and-johnson-dr-paul-janssen-global-innovation-thermosensation
The Rock & Roll Acid Test is more than just a show. It\'s an adrenaline injected, rock fueled perversion of the scientific method. Your hosts will risk bodily harm to prove or disprove some of rocks most enduring myths. Dont miss all the educational fun! And explosions. Did I mention there are explosions? TUESDAYS at 10pm ET on FUSE.
The Rock & Roll Acid Test is more than just a show. Its an adrenaline injected, rock fueled perversion of the scientific method. Yours hosts will risk bodily harm to prove of disprove some of rocks most enduring myths. Dont miss all the educational fun! And explosions. Did I mention there are explosions? TUESDAYS at 10pm ET on FUSE.
www.thespiritconnect for more videos, audio on Astrology, Palmistry, Numerology, Tarot.
Astrology is a group of systems, traditions, and beliefs in which knowledge of the apparent relative positions of celestial bodies and related details is held to be useful in understanding, interpreting, and organizing information about personality, human affairs, and other terrestrial matters. A practitioner of astrology is called an astrologer, or, rarely, an astrologist. Numerous traditions and applications employing astrological concepts have arisen since its earliest recorded beginnings in the 3rd millennium BC.[1][2] It has played a role in the shaping of culture, early astronomy, and other disciplines throughout history.
Astrology and astronomy were often indistinguishable before the modern era, with the desire for predictive and divinatory knowledge one of the primary motivating factors for astronomical observation. Astronomy began to diverge from astrology after a period of gradual separation from the Renaissance up until the 18th century. Eventually, astronomy distinguished itself as the scientific study of astronomical objects and phenomena without regard to the astrological speculation of these phenomena.
Lancôme is unveiling Genes Day on October 22, a one day fundraiser in support of St. Jude Children’s Research Hospital.
In celebration of the beauty of scientific research, Lancôme will donate $7 from each bottle of their latest skin care breakthrough, Génifique Youth Activating Concentrate, sold that day to St. Jude Children’s Research Hospital to support the research and treatment at St. Jude.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/lancome/46646/
